Signal Advisors Wealth LLC Buys 4,464 Shares of Novo Nordisk A/S (NYSE:NVO)

Signal Advisors Wealth LLC increased its stake in Novo Nordisk A/S (NYSE:NVO) by 39.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,874 shares of the company’s stock after purchasing an additional 4,464 shares during the period. Signal Advisors Wealth LLC’s holdings in Novo Nordisk A/S were worth $1,365,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the 2nd quarter valued at about $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the third quarter valued at approximately $28,000. Abound Wealth Management raised its position in Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after purchasing an additional 157 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S during the third quarter worth $42,000. Finally, Carolina Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at $48,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.1 %

Shares of NYSE NVO opened at $84.43 on Tuesday. The stock has a market cap of $378.88 billion, a P/E ratio of 27.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The firm has a 50 day moving average price of $99.84 and a two-hundred day moving average price of $118.61. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52-week low of $81.50 and a 52-week high of $148.15.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NVO. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.